Hypertension and peptides — the bidirectional pharmacology, the natriuretic-peptide cautionary tale, and the modest GLP-1 signal

Why this dossier exists

Hypertension is the indication where peptide pharmacology runs in two directions at once. The same molecular family containing the body's most potent endogenous blood-pressure-lowering hormones — atrial, B-type, and C-type natriuretic peptides — also contains exogenous agents that acutely raise blood pressure and carry uncontrolled-hypertension contraindications on their FDA labels. The GLP-1 receptor agonist class produces modest, consistent reductions in systolic blood pressure across the cardiovascular-outcome trials of 2016–2024. The melanocortin-receptor class produces transient BP elevations that ended the intranasal bremelanotide program for male erectile dysfunction and anchor the labeled contraindications for PT-141 and the unlabeled safety profile of Melanotan II. Nesiritide (recombinant BNP) reached FDA approval in 2001, was the first new heart-failure drug in over a decade, and was effectively withdrawn in 2018 after the O'Connor et al., NEJM 2011 ASCEND-HF trial failed both coprimary endpoints in 7,141 patients. The cautionary tale of peptide cardiovascular pharmacology lives in that arc.

This dossier walks the peptide and peptide-adjacent evidence base for blood pressure across both directions, separates trial-supported signals from mechanism extrapolation, and frames the picture against the small-molecule antihypertensive backbone. The honest read: the GLP-1 class produces 2–5 mmHg systolic reduction consistent across the Sun F et al., Diabetes Res Clin Pract 2015, 110(1):26–37 network meta-analysis of 60 trials and the cardiovascular-outcome trials Marso et al. 2016 LEADER, Marso et al. 2016 SUSTAIN-6, and Lincoff et al. 2023 SELECT; the Whelton et al., Hypertension 2018, 71(6):e13–e115 ACC/AHA 2017 guideline that defined hypertension at ≥130/80 mmHg places roughly 46% of US adults inside the diagnosis; and no peptide currently holds a primary disease-modifying position for hypertension as an isolated indication.